Amylyx Pharmaceuticals, Inc. (AMLX)

USD 3.94

(-7.94%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019
Revenue 380.78 Million 22.23 Million 285 Thousand 650 Thousand 1.42 Million
Cost of Revenue 25.44 Million 2.99 Million 52 Thousand 24.59 Million 11.89 Million
Gross Profit 355.34 Million 19.23 Million 233 Thousand -23.94 Million -10.47 Million
Operating Expenses 316.54 Million 220.57 Million 82.68 Million 39 Million 13.55 Million
Selling, General and Administrative Expenses 188.35 Million 127.12 Million 38.93 Million 15.06 Million 3.08 Million
Research and Development Expenses 128.18 Million 93.45 Million 44.04 Million 24.59 Million 11.89 Million
Other Expenses - 3.74 Million -285 Thousand -650 Thousand -1.42 Million
Cost and Expenses 341.98 Million 223.57 Million 82.68 Million 39 Million 13.55 Million
Operating Income 38.8 Million -201.34 Million -82.68 Million -39 Million -13.55 Million
Interest Expense - 4.29 Million - 2.28 Million 1.27 Million
Income Tax Expense 5.02 Million 774 Thousand -52 Thousand 2.55 Million 1.1 Million
Earnings before Tax 54.29 Million -197.6 Million -87.93 Million -42.28 Million -13.71 Million
Net Income 49.27 Million -198.37 Million -87.87 Million -44.83 Million -14.81 Million
Earnings Per Share Basic 0.73 -2.98 -1.52 -0.79 -0.26
Earnings Per Share Diluted 0.70 -2.98 -1.52 -0.79 -0.26
Weighted Average Shares Outstanding 67.23 Million 66.51 Million 57.86 Million 56.46 Million 56.46 Million
Weighted Average Shares Outstanding (Diluted) 69.99 Million 66.51 Million 57.86 Million 56.46 Million 56.46 Million
Gross Margin 0.93 0.87 0.82 -36.84 -7.34
EBIT Margin 0.10 -9.06 -290.13 -59.57 -9.38
Profit Margin 0.13 -8.92 -308.35 -68.98 -10.39
EBITDA 39.89 Million -200.85 Million -82.63 Million -39 Million 1.11 Million
Earnings Before Tax Margin 0.10 -9.06 -290.13 -60.01 -9.50

Income Statement Charts